Advertisement

Clinical Drug Investigation

, Volume 14, Issue 3, pp 221–225 | Cite as

Lack of Interaction Between Pizotifen and the Novel Antimigraine Compound Zolmitriptan in Healthy Volunteers

  • Emma J. Seaber
  • C. Gillotin
  • R. Mohanlal
  • G. Layton
  • J. Posner
  • R. Peck
Drug Interactions

Summary

This double-blind, randomised, two-period crossover study investigated the effect of pizotifen on the pharmacokinetics and tolerability profile of zolmitriptan (formerly 311C90), a novel selective 5-HT1D receptor agonist for acute migraine therapy. 13 healthy volunteers (mean age 31 years, range 19 to 41 years; mean weight 75kg, range 62 to 89kg) received oral pizotifen 1.5mg or placebo once daily for 8 days with a washout period of at least 2 weeks between study periods. Oral zolmitriptan 10mg was administered with the final dose of pizotifen or placebo. Pizotifen did not significantly affect the pharmacokinetic parameters of zolmitriptan, although in 4 subjects the time to peak plasma zolmitriptan concentration (tmax) was increased in the presence of pizotifen (median increase 1.4 hours). Zolmitriptan caused a small, transient, clinically insignificant increase in blood pressure, which was not affected by pizotifen. No clinically relevant changes in heart rate or 12-lead ECGs were observed. One volunteer was withdrawn because of a brief, 5-beat run, asymptomatic episode of ventricular tachycardia 170 minutes after administration with zolmitriptan plus placebo; this was not considered related to the treatment. Zolmitriptan was well tolerated both alone and in combination with pizotifen. Thus, there is no contraindication to the use of zolmitriptan nor a need for dosage modification in patients concomitantly receiving pizotifen.

Keywords

Migraine Sumatriptan Drug Invest Zolmitriptan Pizotifen 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Martin GR. Inhibition of the trigemino-vascular system with 5-HT1D agonist drugs: selectively targeting additional sites of action. Eur Neurol 1996; 36 Suppl. 2: 13–8PubMedCrossRefGoogle Scholar
  2. 2.
    Dahlöf C, Diener HC, Goadsby PJ, et al. A multicentre double-blind, placebo-controlled, dose range finding study to investigate the efficacy and safety of oral doses of 311C90 in the acute treatment of migraine. Headache 1995; 35: 292Google Scholar
  3. 3.
    Ferrari MD. The clinical effectiveness of 311C90 in the acute treatment of migraine. Eur Neurol 1996; 36 Suppl. 2: 4–7PubMedCrossRefGoogle Scholar
  4. 4.
    Visser WH, Klein KB, Cox RC, et al. 311C90, a new central and peripherally acting 5-HT1D receptor agonist in the acute oral treatment of migraine: a double-blind, placebo-controlled, dose range finding study. Neurology 1996; 46: 522–6PubMedCrossRefGoogle Scholar
  5. 5.
    Lance J. Treatment of migraine. Lancet 1992; 339: 1207–9PubMedCrossRefGoogle Scholar
  6. 6.
    Speight TM, Avery GS. Pizotifen (BC-105): a review of its pharmacological properties and its therapeutic efficacy in vascular headaches. Drugs 1972; 3: 159–203PubMedCrossRefGoogle Scholar
  7. 7.
    Capildeo R, Rose FC. Single-dose pizotifen, 1.5mg nocte: a new approach in the prophylaxis of migraine. Headache 1982; 22: 272–5PubMedCrossRefGoogle Scholar
  8. 8.
    Dixon R, Gillotin C, Gibbens M, et al. The pharmacokinetics and effects of blood pressure of multiple doses of the novel antimigraine drug zolmitriptan (311C90) in healthy volunteers. Br J Clin Pharmacol 1997; 43: 273–81PubMedCrossRefGoogle Scholar
  9. 9.
    Koch GG. The use of non-parametric methods in the statistical analysis of the 2-period crossover design. Biometrics 1972; 28: 577–84PubMedCrossRefGoogle Scholar
  10. 10.
    Seaber E, On N, Dixon R, et al. The absolute bioavailability and metabolic disposition of the novel anti-migraine compound zolmitriptan. Br J Clin Pharmacol 1997. In pressGoogle Scholar
  11. 11.
    Giorgi L, Dixon R, Touw K. Cardiovascular safety of the novel antimigraine compound 311C90 [abstract P18]. Cephalalgia 1995; 15 Suppl. 14: 220Google Scholar
  12. 12.
    Earl NL. Clinical safety of 311C90: aggregated data from patients and volunteers to date. Eur Neurol 1996; 36 Suppl. 2: 8–12PubMedCrossRefGoogle Scholar
  13. 13.
    Stinson JC, Pears JS, Williams AJ, et al. Use of 24h ambulatory ECG recordings in the assessment of new chemical entities in healthy volunteers. Br J Clin Pharmacol 1995; 39: 651–6PubMedCrossRefGoogle Scholar

Copyright information

© Adis International Limited 1997

Authors and Affiliations

  • Emma J. Seaber
    • 1
  • C. Gillotin
    • 1
  • R. Mohanlal
    • 1
  • G. Layton
    • 1
  • J. Posner
    • 1
  • R. Peck
    • 1
  1. 1.Glaxo Wellcome Research and DevelopmentGreenfordEngland

Personalised recommendations